HIKMA Pharmaceuticals PLC — Director's Dealing 2014

May 6, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3522G

Hikma Pharmaceuticals Plc

06 May 2014

Annex DTR3

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

All relevant boxes should be completed in block capital letters

1.	Name of the Issuer: Hikma Pharmaceuticals PLC	2.	State whether the notification relates to (i) a transaction notified in accordance with DTR 3.1.2 R, (ii) a disclosure made in accordance with LR 9.8.6R(1) or (iii) a disclosure made in accordance with section 793 of the Companies Act (2006): DTR 3.1.2 R
3.	Name of person discharging managerial responsibilities/director: Samih Darwazah, Said Darwazah, Mazen Darwazah and Ali Al-Husry	4.	State whether notification relates to a person connected with a person discharging managerial responsibilities/ director named in 3 and identify the connected person: Yes:  Darhold Limited
5.	Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest: Beneficial interest Darhold Limited	6.	Description of shares (including class), debentures or derivatives or financial instruments relating to shares: Ordinary Shares
7.	Name of registered shareholders(s) and, if more than one, the number of shares held by each of them: Bank Julius Baer & CO. LTD.	8.	State the nature of the transaction: Grant of a pledge over 5,000,000 Ordinary Shares in support of a loan
9.	Number of shares, debentures or financial instruments relating to shares acquired: None	10.	Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage): N/A
11.	Number of shares, debentures or financial instruments relating to shares disposed: None	12.	Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage): N/A
13.	Price per share or value of transaction: N/A	14.	Date and place of transaction: London, 2 May 2014
15.	Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage): 57,183,028 - 28.85 per cent.	16.	Date issuer informed of transaction: 6 May 2014

If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes
17.	Date of grant	18.	Period during which or date on which exercisable
19.	Total amount paid (if any) for grant of the option	20.	Description of shares or debentures involved (class and number)
21.	Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise	22.	Total number of shares or debentures over which options held following notification
23.	Any additional information	24.	Name of contact and telephone number for queries

Name of authorised official or issuer responsible for making notification
Peter Speirs, Company Secretary, Hikma Pharmaceuticals PLC
Date of notification:  6 May 2014

Notes:

This form is intended for use by an issuer to make a RIS notification required by DTR 3.1.4

(1)           An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)           An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)           An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4)           An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

Annex DTR3

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

All relevant boxes should be completed in block capital letters

25.	Name of the Issuer: Hikma Pharmaceuticals PLC	26.	State whether the notification relates to (i) a transaction notified in accordance with DTR 3.1.2 R, (ii) a disclosure made in accordance with LR 9.8.6R(1) or (iii) a disclosure made in accordance with section 793 of the Companies Act (2006): DTR 3.1.2 R
27.	Name of person discharging managerial responsibilities/director: Samih Darwazah, Said Darwazah, Mazen Darwazah and Ali Al-Husry	28.	State whether notification relates to a person connected with a person discharging managerial responsibilities/ director named in 3 and identify the connected person: Yes:  Darhold Limited
29.	Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest: Beneficial interest Darhold Limited	30.	Description of shares (including class), debentures or derivatives or financial instruments relating to shares: Ordinary Shares
31.	Name of registered shareholders(s) and, if more than one, the number of shares held by each of them: HSBC Private Bank (Suisse) S.A.	32.	State the nature of the transaction: Release of a pledge over 7,000,000 Ordinary Shares
33.	Number of shares, debentures or financial instruments relating to shares acquired: None	34.	Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage): N/A
35.	Number of shares, debentures or financial instruments relating to shares disposed: None	36.	Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage): N/A
37.	Price per share or value of transaction: N/A	38.	Date and place of transaction: London, 2 May 2014
39.	Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage): 57,183,028 - 28.85 per cent.	40.	Date issuer informed of transaction: 6 May 2014

If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes
41.	Date of grant	42.	Period during which or date on which exercisable
43.	Total amount paid (if any) for grant of the option	44.	Description of shares or debentures involved (class and number)
45.	Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise	46.	Total number of shares or debentures over which options held following notification
47.	Any additional information	48.	Name of contact and telephone number for queries

Name of authorised official or issuer responsible for making notification
Peter Speirs, Company Secretary, Hikma Pharmaceuticals PLC
Date of notification:  6 May 2014

Notes:

This form is intended for use by an issuer to make a RIS notification required by DTR 3.1.4

(1)           An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)           An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)           An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4)           An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBBGDUCUGBGSL